Propanc Health Group Corporation (OTCQB: PPCH) Rallies 9% After Announcing Presentation At Global Investment Conference

Google Ads

By: Matt Rego

Propanc Health Group Corporation (OTCQB: PPCH) specializes in treatments for various cancers, such as pancreatic and colorectal cancers in Australia. The health corporation is seeing shares rally 9% on heavy volume on Thursday, August 04, 2016. Over the past three months, Propanc Health Group Corporation (OTCQB: PPCH) has seen average daily volume of around 5.62 million shares. However, nearly 6.93 million shares or dollar volume of $138,600 has already exchanged hands on Thursday.

The cancer treatment company caught a bid today after the company announced they would be presenting at Rodman and Renshaw’s 18th Annual Global Investment Conference. The conference is scheduled to take place on September 12, 2016 at 5:30 Eastern Time, at the New York Palace Hotel in New York City. The global investment conference will give Propanc Health Group Corporation (OTCQB: PPCH) a chance to show its new cancer therapy treatments, methods, supportive data, and more to an audience of global investors. Here is the press release detailing of the presentation:

Propanc Health Group Corporation (OTCQB: PPCH) Press Release

MELBOURNE, AUSTRALIA–(Marketwired – August 03, 2016) – Propanc Health Group Corporation (PPCH) (“Propanc” or “the Company”), an emerging healthcare company focusing on development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers, today announced the Company will present at Rodman and Renshaw’s 18th Annual Global Investment Conference, at the New York Palace Hotel, New York City, on Monday, September 12th, 2016, at 5:30pm, Eastern Daylight Time.

The presentation will focus on the latest research undertaken by the Company’s for its lead product, PRP, as a method to treat and prevent metastatic cancer. PRP’s unique patented approach suppresses metastasis and tumor relapse, complementing conventional therapies and is safe at specified dosages with minimal toxicity.

“We are waging a fight against cancer, but while conventional therapies kill cancer cells that replicate, deep inside are a smaller number of cells, known as cancer stem cells, that resist attack,” said James Nathanielsz, Propanc’s Chief Executive Officer. “To achieve a total victory over cancer, we need to target and eradicate cancer stem cells. Our lead product, PRP, is a new therapeutic approach consisting of two pancreatic proenzymes which stops the cancer stem cell machinery by turning them back into normal cells. I look forward to presenting our latest scientific data, as well as outlining our progress towards first-in-man studies in 2017.”

Dr Julian Kenyon, Propanc’s Chief Scientific Officer added, “It’s a new frontier in cancer therapy and PRP is helping lead the way by turning off and curtailing the population of cancer stem cells whilst leaving healthy cells unharmed. PRP offers new hope for clinicians and their patients to greatly improve survival. It has the potential to transform cancer care. I am pleased to present our data to the broader investment community at such a reputable conference.”

Google Ads

The Company aims to fast track the development of proenzyme related oncology products into clinical trials initially for pancreatic and ovarian cancers, followed by colorectal cancer. According to Global Analyst Reports, the combined world market for pancreatic, ovarian and colorectal cancers are expected to reach over $12 billion by 2020.

About Propanc:

Propanc is developing new cancer treatments for patients suffering from pancreatic, ovarian and colorectal cancers. We have developed a formulation of anti-cancer compounds, which exert a number of effects designed to control or prevent tumors from recurring and spreading throughout the body. Our products involve or employ pancreatic proenzymes, which are inactive precursors of enzymes.

In the near term, we intend to target patients with limited remaining therapeutic options for the treatment of solid tumors. In future, we intend to develop our lead product to treat (i) early stage cancer and (ii) pre-cancerous diseases and (iii) as a preventative measure for patients at risk of developing cancer based on genetic screening. For more information, visit:

Related Articles

Leave a Reply

Your email address will not be published.

Back to top button